H1B Visa Data for Edward Gary Farwell: Cases Handled,Cases Certified, Approval Rate

We now have Quarter 4 H1B visa FY 2023 data and Quarter 4 PERM visa FY 2023 data and Quarter 4 H2A visa FY 2023 data.
Employer Search tool is moved to it's own page: "H1B Visa Data Search Tool"

Statistics and Summary

Edward Gary Farwell has been assisting clients through the H1B Visa process since 2023.

As of 2022, Edward Gary Farwell has succesfully submitted and recieved certification for 32 cases.

Edward Gary Farwell is located in Boston, MA, and has represented 11 employers for the H1B Visa Process

32
Cases Handled

32
Cases Certified

100.00%
Approval

Cases Handled by Edward Gary Farwell

Case Number	Case Status	Job Title	Industry Name	Employer Name	Year
I-200-23206-214703	Certified	Sales Engineers	Custom Computer Programming Services	Inpher Inc	2023
I-200-22292-538796	Certified	Sales Engineers	Custom Computer Programming Services	Inpher Inc	2023
I-200-22054-923656	Certified	Political Scientists	International Affairs	Turkish Heritage Organization Inc	2022
I-200-22041-893211	Certified	Political Scientists	International Affairs	Turkish Heritage Organization Inc	2022
I-200-21029-042118	Certified	Chemists	Research And Development In Biotechnology Except Nanobiotechnology	Acceleron Pharma Inc	2021
I-200-23011-694495	Certified	Molecular And Cellular Biologists	Research And Development In Biotechnology Except Nanobiotechnology	Arrakis Therapeutics Inc	2023
I-200-23064-823582	Certified	Microbiologists	Research And Development In Biotechnology Except Nanobiotechnology	Arrakis Therapeutics Inc	2023
I-200-23124-990755	Certified	Biochemists And Biophysicists	Research And Development In Biotechnology Except Nanobiotechnology	Arrakis Therapeutics Inc	2023
I-200-21152-358840	Certified	Biochemists And Biophysicists	Research And Development In Biotechnology Except Nanobiotechnology	Acceleron Pharma Inc	2021
I-200-21144-338578	Certified	Biochemists And Biophysicists	Research And Development In Biotechnology Except Nanobiotechnology	Acceleron Pharma Inc	2021